Chronic Kidney Disease, Insulin Resistance, Vitamin D Deficiency
Conditions
Keywords
renal disease, renal impairment, chronic kidney disease stage 3-4, 25(OH) vitamin D, cholecalciferol, vitamin D deficiency, insulin resistance, insulin-glucose clamp, non-diabetic
Brief summary
The purpose of this study is to evaluate the impact of vitamin D3 supplementation on the insulin resistance in non-diabetic patients with chronic kidney disease (CKD) stages 3-4, vitamin D deficiency/insufficiency and elevated fasting serum insulin levels.
Detailed description
Insulin resistance, i.e., reduction in insulin responsiveness with a decrease in glucose uptake in insulin target tissues (muscle and adipose tissue) is common in end-stage renal disease (ESRD), but is also present at earlier stages of renal disease with mild-moderate renal function impairment as well as in microalbuminuria and nephrotic syndrome. Population-based cross-sectional studies have shown that low levels of vitamin D (25(OH) vitamin D) is associated with impaired glucose tolerance in subjects with normal renal function and that reduced renal function and 25(OH) vitamin D deficiency are independently associated with insulin resistance. Vitamin D has well-known effects on calcium metabolism and skeletal mineralisation but recent experimental studies suggest that vitamin D in addition reduces several inflammatory mediators that are of importance in the development and progression of renal disease which also associated with insulin resistance such as TNF-α and IL-6. This is a prospective, single-blind, explorative, randomized, placebo-controlled, single-centre, two-way cross-over study with two treatment periods of 10 weeks separated by a washout period of 6 weeks. Non-diabetic patients with chronic kidney disease (CKD) stage 3 and 4 (GFR 15-60 ml/min/1.73m2) who have low serum 25-OH-vitamin D levels (\< 30 ng/mL) and elevated fasting serum insulin levels (\>10 IU/L) will be randomized to receive either vitamin D3 (cholecalciferol) 3200U orally (tablets) daily or placebo. Approximately 24 patients are going to complete the study. A pre-entry wash-out period of 6 weeks is needed for patents already on vitamin D treatment. An in vivo assessment of insulin secretion and insulin sensitivity will be made by insulin-glucose clamp at the end of each treatment period.
Interventions
DRUGcholecalciferol (TillVal-D)
In a randomized, two-way cross-over design participants will take vitamin D3 or placebo twice daily during treatment periods of 10 weeks separated by a washout period of 6 weeks.
DRUGPlacebo
Placebo orally twice daily
Sponsors
Sahlgrenska University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female, age older than 18 years 2. Non-diabetic chronic kidney disease stage 3 and 4 (GFR 15-60 ml/min/1.73 m2) 3. Serum 25(OH) vitamin D \< 30 ng/mL (75 nmol/L) 4. Fasting S-insulin \> 30 IU/L 5. Written informed consent before entered into study
Exclusion criteria
1. Patients with current significant, major or unstable cardio-cerebrovascular, infection, respiratory, gastrointestinal or other major disease and risks according to the judgment made by the investigator 2. Patients with type 1 or type 2 Diabetes 3. Current severe thyrotoxicosis or other endocrine disease 4. Granulomatous disease, such as sarcoidosis and tuberculosis 5. Patients who are intended to receive hemodialysis (HD), peritoneal dialysis (PD) or being kidney transplanted during the course of study (9 months) 6. Concomitant use of corticosteroids (except for inhalation or topical use) or other immunosuppressive medication 7. Treatment with biphosphonate during last two years 8. S-Calcium \> 2.70 mmol/L (0.68 mg/dl) 9. PTH intact \< 75 ng/L (8.25 nmol/L) or \> 800 ng/L (88 nmol/L) 10. Proteinuria \> 3.5 g/24 hours 11. Alcohol or drug abuse or any condition associated with poor compliance 12. Blood donors 13. Women of childbearing potential, desired pregnancy, pregnancy or lactation within the study period 14. Allergy or intolerance to cholecalciferol supplementation (TillVal D®) or other constituents 15. Participation in a clinical trial evaluating an investigational drug in the last 12 weeks prior to inclusion to this trial 16. History of kidney stones 17. History of chronic hepatitis or liver enzymes (ASAT or ALAT) more than 2.5 times the upper limit of normal 18. Gastrointestinal disease resulting in significant gastrointestinal dysfunction or malabsorption 19. Use of medications known to interact with vitamin D metabolism such as cholestyramine, phenytoin, digitalis and antacids 20. Planned vacation with high sun exposure during the study period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in M-value (mg/kg lean body mass/min) assessed by insulin-glucose clamp | at week 26 |
Secondary
| Measure | Time frame |
|---|---|
| Change in systolic- and diastolic blood pressure | at week 26 |
| Change in PTH secretion and its fragments assessed by PTH, CAP-PTH, CIP-PTH | at week 26 |
| Change in insulin secretion assessed by intravenous glucose tolerance test | at week 26 |
| Change in urinary excretion of albumin (UAE) assessed by 24 hour collection | at week 26 |
Countries
Sweden
Outcome results
None listed